Covid vaccines are once again on the agenda for the Centers for Disease Control and Prevention’s vaccine advisory panel.
Moderna has announced that the FDA will initiate the review of its seasonal influenza vaccine candidate, mRNA-1010.
Q4 2025 Earnings Call February 24, 2026 4:30 PM ESTCompany ParticipantsAndrew Guggenhime - President & CFOGrant Pickering ...
Merck (NYSE:MRK) announced a major reorganization of its Human Health business into two global units focused on Oncology and ...
Background Respiratory syncytial virus (RSV) is a leading cause of infant hospitalisation due to lower respiratory tract infections. Until 2022, prevention was limited to the costly monoclonal ...
The Pharmerging Market refers to the rapidly expanding pharmaceutical sectors in emerging economies, fueled by rising ...
Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 - - Advancement reflects continued execution of ...
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued stocks in the Biotechnology industry for Wednesday, February 25, 2026. Let’s ...
Tempo verified the information by examining the Epstein Files, comparing them with credible sources, and interviewing public ...
Due to Pfizer’s underperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautious ...
Kennedy Jr. leading the charge—scientific literature is building a wondrous story: A vaccine appears to prevent dementia, including Alzheimer’s, and may even slow biological aging. For years, study ...
Sanofi is leading commercialization efforts for Nuvaxovid and Novavax is eligible to receive ongoing tiered royalties from sales of the vaccine. A full 12-month commercial cycle under Sanofi’s control ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results